Category Archives: J. CONDITIONS TO TREAT

Cannabinoid-receptor blocker will probably not be sold in the US

The New York Times reports, “The [FDA] advisory panel voted unanimously, 14 to 0, against recommending the drug [rimonabant, Acomplia, Zimulti], saying there was inadequate evidence of its safety. The FDA is not required to follow this advice, but it typically does.”

The report is interesting to this blog because rimonabant works by blocking cannabinoids receptors in the brain. Continue reading Cannabinoid-receptor blocker will probably not be sold in the US →